roche: Can Google, Amazon take on pharma’s mantle? Biotech giant Roche’s founders weigh in on the scenario.
1 year ago
From left, Jörg Duschmalé, member of board, Roche; André Hoffmann, Vice chairman of the board of directors, Roche. image courtesy: Roche.
Synopsis
Powered by the highest research spending in the industry, the world’s largest biotechnology company has built an array of first-in-class, industry-leading blockbusters. Besides, it keeps filling the revenue void left by patent expirations. André Hoffmann and Jörg Duschmalé, part of Roche’s founding family and board, share their thoughts on research, data, ownership, and management strategy.
A deadly cholera pandemic in 1896 triggered a scientific pursuit that created the world’s biggest biotechnology company, Roche. After an epochal journey of 125 years, Roche notched up sales of USD65 billion and a net income of USD15.4 billion last year. Although Roche may not be a household name in India, it has earned an enviable spot in the global pharmaceutical landscape. Over the years, the company has built an array of first-in-class,
BY
ET Prime
8 mins read, Last Updated:
Gift A Story
Share member-only stories with your friends or family and help them read it for free.
Gifting Limit Reached!
Hey , no more stories left for you to gift.
No worries! You will get a limit of 15 stories next month to share with your friends and family.
Gift This Story
Stories Left!
You can gift upto 15 stories in a month.
FONT SIZE
AbcSmall
AbcMedium
AbcLarge
SAVE
PRINT
COMMENT
Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories & personalised newsletters
Login Now
Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions & in-depth stock reports
Subscribe Now
To read full story, subscribe to ET Prime
Get Unlimited Access to The Economic Times
₹34 per week
Billed annually at ₹2499 ₹1749
Already a Member? Sign In now
Already a Member? Sign In now
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
Rs 49 for 1st month
Then Rs. 1,749 per year
SUBSCRIBE NOW
Valid only with UPI, Credit & Debit Cards Autopay
Choose Payment Mode & Plan
–
–
–
Subscribe Now
(Credit card mandatory)
You can cancel your subscription anytime
–
–
–
Subscribe Now
(Pay Using Netbanking/UPI/Debit Card)
Netbanking, Credit & Debit Card
Subscribe with Google
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial +Includes DocuBay and TimesPrime Membership.
₹399
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial +Includes DocuBay and TimesPrime Membership.
Get ET Prime for just ₹2499 ₹1749/yr
BIG WIN OFFER
Get 6 Months Free
WITH 1-YEAR ET PRIME MEMBERSHIP
Avail Offer
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with Minimal Ads
Comment & Engage with ET Prime community
Exclusive invites to Virtual Events with Industry Leaders
A trusted team of Journalists & Analysts who can best filter signal from noise
